Abstract: Novel compositions for the disguising of facial blemishes and scars in human users are disclosed. In addition, methods for utilizing said compositions, as well as kits for packaging and holding products containing said compositions, are disclosed. The novel compositions disclosed are based on a silicone material which is pre-mixed with a catalyst and an adhesion promotor, and sometimes also with a flocking agent. These pre-mixed compositions represent a significant improvement in product simplicity and ease of use for the person using the product. The methods disclosed are for utilizing products made from the claimed compositions and include simple dispensing of the silicone mixture followed by application of a skin texturing pad. The prescribed use of the skin texturing pad in the claimed methods is essential to create texture. Finally, kits for dispensing the primer-less silicone mixtures and for packaging the products are disclosed.

Abstract: Disclosed is a method of treating the hair, the method comprising: a) applying to the hair a shampoo composition comprising a detersive surfactant, wherein the shampoo composition is substantially free of silicone conditioning agents and/or cationic conditioning polymers; b) rinsing the shampoo composition from the hair; c) applying to the hair a conditioning composition comprising a silicone resin and an aminosilicone, wherein the aminosilicone has non-quaternized and/or quaternary amine functional groups. The present invention provides improved conditioning benefits such as hair manageability and/or reduced frizziness/friction.

Abstract: An anhydrous personal care composition, comprising: (a) 45 to 60 weight % of at least one ester, selected from (i) triglycerides, (ii) diglycerides, (iii) monoglycerides, (iv) monoesters of diols, and (v) diesters of diols; (b) a first wax having a melting point of from 35° C. to 72° C. present in an amount of 5 to 25 weight %; (c) a second wax having a melting point of 73 to 90° C. present in an amount of 0.5 to 15 weight %; and (d) at least one plant oil having a saponification value of from 150 to 275 mg KOH/g present in an amount of 5 to 35 weight.

Abstract: Provided are methods of treating skin with extracts of Tiliacora plants to improve the health and/or diminish signs of aging. In various implementations, the Tiliacora triandra plant is hydroponically grown and/or is capable of stimulating hyaluronic acid production in human fibroblast cells. Skincare compositions comprising the extracts are also provided.

Abstract: Disclosed is a method for reducing the appearance of a wrinkle on skin comprising topically applying to said wrinkle a composition that includes an effective amount of ornithine, retinol, Commiphora mukul resin or an extract thereof, and hyaluronic acid, wherein topical application of the composition reduces the appearance of said wrinkle within 120 seconds after application of the composition, and wherein topical application of said composition stimulates adipogenesis in said skin.

Abstract: A method for the permanent shaping and color modification of keratinic in a single process includes the following steps. First, an aqueous composition, including at least one keratin-reducing compound and at least one alkalizing agent, is applied to the keratinic fibers and is left on the keratinic fibers for a period of 5 to 50 minutes at a temperature of 20 to 45° C. The keratinic fibers are rinsed, and optionally dried. Next, a composition including at least one oxidation dye precursor and at least one oxidizing agent is applied to the keratinic fibers and the keratinic fibers are deformed. That composition is allowed to act for 10 to 35 minutes. An aqueous composition including at least one oxidizing agent, is applied to the keratinic fibers for 30 seconds to 15 minutes. The keratinic fibers are rinsed out, along with removal of the deformation aids.

Abstract: A composition comprising an extract from damaged plant parts from the Moringaceae genus, at least one oligopeptide, at least one extract from the Laminaria genus, and whey protein and a method for stimulating collagen synthesis in skin cells.

Abstract: A method useful for inhibiting moisture loss from skin comprises the step of administering a composition to a subject's skin. The composition comprises a first humectant and a second humectant different from the first humectant. The humectants are useful for increasing moisture content of the subject's skin, specifically the subject's epidermis. The first humectant may comprise a conventional humectant, e.g. glycerol. The second humectant generally comprises certain types of honey. The honey is capable of inhibiting moisture loss from the subject's epidermis and/or moisture loss from the first humectant when the subject is exposed to dry air conditions, e.g. wintertime air having a relative humidity of about 50% or less. Specifically, the second humectant is useful for mitigating adverse effects of the first humectant under certain conditions.

Abstract: A method of forming a kit containing multiple dissolvable unit dose constructs includes providing at least one muco-adhesive composition comprising a polymer matrix, the polymer matrix comprising a water soluble polymer, an active ingredient and a liquid carrier; forming a plurality of dissolvable thin film unit dose constructs by depositing the at least one composition onto a substrate wherein at least two adjacent dissolvable thin film unit dose constructs are formed having a pre-determined different identifiable physical characteristic with respect to the other as a result of the depositing; and packaging the plurality of dissolvable thin films in a single package to form a kit.

Abstract: The present disclosure concerns effervescent compositions and methods of making and using the same. In some embodiments, the disclosed effervescent compositions are formed from an input blend comprising an acid and a base by granulating the input blend in a twin-screw processor. The granules formed from the input blend can be formed by an in situ granulating agent, which can be a portion of the acid that melts during granulation. In some embodiments, the effervescent compositions can be made using a twin-screw processor comprising an intake zone for receiving an input blend comprising an acid and a base; a granulation initiation zone for melting only a portion of the acid to serve as an in situ granulating agent; a granulation completion zone for granulating the input blend; and an outlet for discharging the granules.

Abstract: A topical composition for skin repair comprising selenosugars of formula (1): (Formula (I)) wherein, n is 1, 2 or 3; m is 2, 3, 4; or 5; and each R1 is independently-(optionally substituted C1-C3 alkyiene)p-OH, where p is 0 or 1 or a pharmaceutically acceptable salt thereof.

Abstract: The invention provides a process for the standardization of subcutaneous allergen immunotherapy formulas resulting in increasing availability and decreasing costs, allowing for expanded and improved relief for a greater number of allergy sufferers. This invention provides a lower cost treatment to increase availability of the benefits of subcutaneous immunotherapy via standardization of most common seasonal or year round allergens for treatment. Standardizing a formula containing multiple allergen types allows a large population of potential users to benefit from a wide spectrum of included allergen sensitivities. Mass production of non-customized formulas allows for cost reduction, which breaks down a major barrier to current demand. The availability of non-individualized reduced allergen extract concentration strength formula allows for cost-effective availability in less-specialized delivery channels, which breaks down the other major barrier to current demand.

Abstract: Novel compositions for performance-enhancing nasal irrigation, nasal irrigation apparatus for delivering said performance-enhancing compositions, and methods for enhancing performance using said compositions. Any combination of salt, baking soda, one or more alkaline earth metals, one or more amino acids, one or more natural antioxidants, one or more plant-based stimulants, one or more vitamins, and one or more synergists or other ingredients are disclosed. The ingredients described herein may be delivered as an anhydrous powder packet containing water-soluble forms of the component ingredients, and may be delivered along with nasal irrigation devices and instructions for mixing the powder with a fixed volume of pure water.

Abstract: Oral dosage forms of osteoclast inhibitors, such as zoledronic acid, in an acid or a salt form can be used to treat or alleviate pain or related conditions, such as complex regional pain syndrome.

Abstract: An orally administrable micellar composition is provided. The composition comprises a pharmaceutical agent encapsulated in micelles formed by at least one micelle-forming compound in a pharmaceutically acceptable aqueous solvent comprising an alkali metal salicylate and a pharmaceutically acceptable edetate combined with at least one physiologically acceptable film forming agent.

Abstract: Disclosed are biocompatible composite nanoparticles and methods of preparing biocompatible composite nanoparticles. Also disclosed ate composite nanoparticles which are biocompatible, biodegradable and have numerous other advantages, and also examples of preparation of the nanoparticles and applications for intracellular delivery.

Abstract: Pharmaceutical compositions and methods are provided to treat headache, headache-associated symptoms, photophobia, or adverse effects associated with the headache. Also provided herein are small smooth particulates comprising a 5HT1B/1D receptor agonist. Compositions for oral administration are described herein wherein the compositions comprise a combination of active agents, such as a 5HT1B/1D receptor agonist and one or more antiemetics.

Abstract: Microbiota restoration therapy (MRT) compositions (e.g., oral MRT compositions) and methods for manufacturing MRT compositions are disclosed. An example method for manufacturing an MRT composition may include collecting a stool sample, purifying the stool sample to form a purified sample, stabilizing the purified sample to form a stabilized sample, converting the stabilized sample to a solid, adding one or more additives and/or excipients to the solid to form a treatment composition, and encapsulating the treatment composition.

Abstract: This invention provides methods for the formation of biocompatible membranes around biological materials using photopolymerization of water soluble molecules. The membranes can be used as a covering to encapsulate biological materials or biomedical devices, as a “glue” to cause more than one biological substance to adhere together, or as carriers for biologically active species. Several methods for forming these membranes are provided. Each of these methods utilizes a polymerization system containing water-soluble macromers, species, which are at once polymers and macromolecules capable of further polymerization. The macromers are polymerized using a photoinitiator (such as a dye), optionally a cocatalyst, optionally an accelerator, and radiation in the form of visible or long wavelength UV light. The reaction occurs either by suspension polymerization or by interfacial polymerization.

Abstract: Contained herein are compositions, formulations, methods, and kits for treating regional fat deposits and fat-related conditions. Certain methods comprise administering tetradecyl sulfate, tetradecyl sulfate-like compounds, and pharmaceutically or cosmetically acceptable salts, solvates, prodrugs, or esters thereof and a liquid carrier.

Abstract: The present invention relates to a pharmaceutical composition for preventing or treating Th1- or Th2-mediated disease, which comprises 4H3MC (4-hydroxy-3-methoxycinnamaldehyde) as an active ingredient. 4H3MC (4-hydroxy-3-methoxycinnamaldehyde) according to the present invention shows the effect of inhibiting T-cell activity without inducing T-cell death. Thus, 4H3MC (4-hydroxy-3-methoxycinnamaldehyde) according to the present invention can be developed into an effective therapeutic agent against Th1- or Th2-mediated disease, etc.

Abstract: This invention is directed to a treating method for DHIC, comprising the step of administering a therapeutically effective amount of 3-(15-hydroxypentadecyl)-2,4,4-trimethyl-2-cyclohexene-1-one, a salt thereof, or a solvate thereof.

Abstract: A method is disclosed for reducing the extent of myocardial cell damage or cell death arising from hypoxia or a loss, reduction or interruption in coronary blood flow comprising administering a pharmaceutical composition which includes riluzole or a pharmaceutically acceptable salt or derivative thereof. The method further discloses administering the pharmaceutical composition to reduce the incidence and severity of arrhythmias arising from the hypoxia or loss, reduction or interruption in coronary blood flow. The method also discloses treating a sequence of pathological events with the pharmaceutical composition wherein the sequence involves a cellular influx of sodium via persistent sodium channels, and the development of myocardial cellular damage or myocardial cellular death.

Abstract: This disclosure relates to methods administering various compounds in conjunction with dextromethorphan to a human being.

Abstract: Formulations and methods are provided for improving the function, i.e. clinical outcome, of solid organ transplants. Lung transplantation is of particular interest. In the methods of the invention, a nanoparticle formulation comprising an effective dose of an iron chelator active agent in nanoparticle form, including without limitation, deferoxamine (DFO), deferasirox (DFX), and deferiprone (DFP), etc. is topically applied to the surface of tissues during episodes of graft rejection.

Abstract: The present invention includes methods of preventing a ceramide-sensitive cancer comprising: identifying a subject that has been treated for the ceramide-sensitive cancer; and providing to the subject an effective amount of a combination of a sphingosine kinase inhibitor and a ceramide inducing agent or a ceramide analog in an amount sufficient to prevent or reduce the recurrence of the ceramide-sensitive cancer.

Abstract: The present invention relates to a cysteine releasing pharmaceutical preparation(s) for novel use in preventing and/or treating alcohol flushing and alcohol induced hypersensitivity reactions. Additionally, the invention relates to a method for eliminating histamine releasing effect of locally formed acetaldehyde in the digestive tract.

Abstract: Omega-3 compositions, dosage forms, and methods of use are disclosed herein. The omega-3 compositions and dosage forms disclosed herein may comprise DHA and EPA at a ratio of about 5:2. The omega-3 compositions and dosage forms disclosed herein may comprise re-esterified triglycerides. Methods of treatment using the compositions and dosage forms are also disclosed.

Abstract: A method of controlling the inflammatory and/or neuropatic pain of various origins by administering a pharmaceutical composition containing palmitoylethanolamide, to a human or animal patient. In particular, the present invention relates to the administration of a pharmaceutical composition comprising palmitoylethanoiamide (PEA) and L-acetylcarnitine (LAC), optionally in addition with an antioxidant compound, such as a polyphenol, alpha-lipoic acid, or L-acetylcysteine to a patient.

Abstract: Provided are: an eicosapentaenoic acid alkyl ester-containing composition which comprises 96-99 area % of an eicosapentaenoic acid alkyl ester, wherein the content of an arachidonic acid alkyl ester is 0.7 area % or less, and the content of mono-trans forms of the eicosapentaenoic acid alkyl ester is 2.5 area % or less; a method for producing a high-concentration eicosapentaenoic acid alkyl ester-containing composition, which comprises performing rectification on an eicosapentaenoic acid alkyl ester-containing composition with the degree of vacuum being 0.2 Torr or less and at a whole-column temperature 190° C. or less, and performing a concentration treatment on the rectified composition using chromatography, the eicosapentaenoic acid alkyl ester-containing composition being obtained by alkyl esterifying a feed oil containing eicosapentaenoic acid.

Abstract: The invention relates to compositions and methods useful for enhancing hair growth and promoting skin regeneration. Particularly, the invention provides topical compositions including trimebutine, salts, or active metabolites thereof, for enhancing or inducing hair growth and promoting skin regeneration. Compositions comprising trimebutine or a pharmaceutically acceptable salt or active metabolite thereof and their use in the method of promoting hair growth or skin regeneration. Preferably trimebutine is trimebutine maleate or N-desmethyl trimebutine. Compositions are preferably in a form for topical administration, such as a gel.

Abstract: This invention provides compounds of Formula I wherein B, G, A, E, R1, R2, R3, m and n are as defined herein, which are useful as type I receptor tyrosine kinase inhibitors, and methods of use thereof in the treatment of hyperproliferative disorders in mammals.

Abstract: The present invention aims to provide a pharmaceutical agent for the prophylaxis and/or treatment of Alzheimer's disease, which has a novel action mechanism and shows less side effects. A polyphenol derivative having liposolubility enhanced by the introduction of at least one kind of a liposoluble group selected from the group consisting of a chain saturated hydrocarbon group, a chain unsaturated hydrocarbon group, a cyclic saturated hydrocarbon group, a cyclic unsaturated hydrocarbon group, an aromatic hydrocarbon group, a liposoluble vitamin residue and a sterol residue has an action to potentiate neprilysin activity, and is useful as a pharmaceutical agent for the prophylaxis and/or treatment of Alzheimer's disease.

Abstract: The present invention relates to a flavonoid-poly(ethylene glycol) complex comprising flavonoid compounds and poly(ethylene glycol) and a preparation method of the same. The flavonoid-poly(ethylene glycol) complex of the invention displays a significantly improved solubility of flavonoid which is usually insoluble in an aqueous solution and contains flavonoid compounds distributed evenly in the complex so that the complex of the invention can be effectively used for the establishment of a method for enhancing solubility of flavonoid in an aqueous solution and a method for enhancing bioavailability of flavonoid.

Abstract: A method of treating a chronic wound in a subject in need of such treatment is provided. The method includes administering to the subject at least one antioxidant agent in an amount effective to treat the wound. in some versions, the antioxidant agent is ?-tocopherol or N-acetyl cysteine, or a combination of these compounds. In other versions, a method of preparing a chronic wound animal model is provided.

Abstract: This invention relates to improved solutions comprising ascorbic acid (vitamin C). These solutions may comprise as much as 15% ascorbic acid; they are stable for at least two years, without no significant development of yellowish coloration and no substantial (not more than 10%) degradation of the vitamin. The process involves sequential additions of ascorbic acid and ethoxydiglycol to a first solution of vitamin in water, which are followed by addition of propylene glycol. The stirring speed that occurs during the additions favors a process of micronization. Mild heating is used to achieve ascorbic acid concentrations equivalent to about 6% in 10% water or higher.

Abstract: The invention is directed to compounds that are specific inhibitors of PKC delta, and methods and compositions for the treatment and prevention of cancers and other disorders. Compositions comprising compounds of the invention are used to treat cancers such as, for example, carcinoid and neuroendocrine tumors, malignant melanomas, pancreatic, gastrointestinal and lung cancers. Neuroendocrine tumor cell lines of pulmonary and gastrointestinal origin are surprisingly sensitive to PKC delta inhibition by the compounds of the invention. The invention is further directed to methods, compositions and kits containing compounds of the formulas (Ia), (IIa), (IIIa), (IVa), and (V) as disclosed and described in FIGS. 11 and 12.

Abstract: This invention provides that Ropinirole (4-[2-(Dipropylamino)ethyl]-1,3-dihydro-2H-indol-2-one) possess potent urease inhibitory potential (in vitro) with 97.3% inhibition and IC50=11.7+0.46 ?M, when compared to the standard inhibitors i.e. acetohydroxamic acid (IC50=41.5+1.50 ?M), and thiourea (IC50=21.0+0.50 ?M).

Abstract: A tumescent contravenom solution including: (a) a vasoconstrictor, (b) a physiological crystalloid solution, and (c) optionally a contravenom agent that neutralizes tissue toxic enzymes present in a venom and/or a drug that impairs or paralyzes lymphatic smooth muscle function and impairs lymphatic transport of venom. Also described are methods of treating an envenomation in a subject, and a kit for performing the method of treating an envenomation.

Abstract: The present invention relates to the field of human health, and more particularly to the treatment of attention deficit/hyperactivity disorder (ADHD) with mazindol. The latter can be administered as monotherapy or in combination with one or more compounds, including psychostimulants, for the indication of ADHD and associated or co-morbid symptoms.

Abstract: A method of treating a bacterial infection in a subject in need thereof includes administering to the subject therapeutically effective amounts of at least one ?-lactam antibiotic and at least one bisthiazolidine metallo-?-lactamase inhibitor.

Abstract: This invention relates generally to a therapeutic use of alkaline phosphatase to modulate gastrointestinal tract flora levels in subject.

Abstract: Methods for inhibiting the growth of pancreatic cancer cells or other cancer cells driven by Sonic hedgehog are disclosed.

Abstract: The present invention relates to compositions and methods of inducing the self-renewal of stem/progenitor supporting cells, including inducing the stem/progenitor cells to proliferate while maintaining, in the daughter cells, the capacity to differentiate into hair cells.

Abstract: Controlled release oral dosage forms suitable for administration of methylphenidate are provided. Abuse-resistant controlled release oral dosage forms suitable for administration of methylphenidate are also provided. Methods of treating ADD and ADHD using the oral dosage forms are also provided.

Abstract: The present invention relates to methods of inducing the self-renewal of stem/progenitor supporting cells, including inducing the stem/progenitor cells to proliferate while maintaining, in the daughter cells, the capacity to differentiate into hair cells. Specifically, the invention relates to methods of using compounds comprising a N-(1H-pyrazol-4-yl)-nicotinamide moiety having a Formula I: and pharmaceutically acceptable salts thereof.

Abstract: This present invention is concerned with novel solid dispersion pharmaceutical compositions for preparation of composition which is comprised of a compound with poor water solubility (a weakly basic, neutral and/or non-ionizable, or a weakly acidic compound), water-soluble polymer(s), pH-sensitive polymer(s) (either enteric polymer or gastric-soluble polymer that is soluble at gastric fluid and insoluble at intestine pH range such as Eudragit E), and/or pharmaceutical acceptable surfactant(s) that would improve the solubility/dissolution of the compound in aqueous media of both low and neutral pHs and provide a relative pH-independent dissolution profile.

Abstract: The present disclosure provides for palonosetron formulations, such as aerosol formulations of palonosetron for pulmonary delivery. Also provided are uses of the formulation, such as reduction, elimination or prevention of nausea and vomiting associated with chemotherapy, radiation therapy, or surgery. Also provided are novel methods to treat chemotherapy-induced nausea and vomiting (CINV), radiation-induced nausea and vomiting (RINV), and post-operative nausea and vomiting (PONV) using the inhalation formulations.

Abstract: A method for treating a subject having, or at risk of having, ataxia, generally includes administering to the subject an amount of a composition comprising a cholecystokinin receptor (Cck1R) agonist effective to ameliorate at least one symptom or clinical sign of ataxia.

Abstract: The present disclosure relates to a pharmaceutical composition comprising two Tyrosine Kinase Inhibitors (TKIs), namely Ceritinib and an EGFR Inhibitor. The present combination can be administered independently or separately, in a quantity which is jointly therapeutically effective for the treatment of a TKI mediated disease, such as cancer. The disclosure also provides the use of such a combination for the manufacture of a medicament; the use of such a combination as a medicine; a kit of part comprising such a combination; and a method of treatment of such a combination.